Over The Counter (OTC)
A Pfizer poll shows patients rely on over-the-counter medications but need help finding the right treatment.
Johnson & Johnson alleged that misleading advertising threatened the $13.2 million in average weekly sales it makes during prime allergy sales season.
The government is asking consumers which ones they prefer.
The drugmaker, which markets the Dimetapp cough and cold line, sent a complaint to the Better Business Bureaus.
The over-the-counter weight-loss drug Alli saw a return to drugstores this week after a year hiatus.
The initial push includes a behind-the-scenes Tumblr and broadcast plans are being finalized.
Pfizer, through the Better Business Bureau's National Advertising Division, disputes that Novartis's Theraflu 'starts to work in the body in 5 minutes.'
The FDA has approved a 24-hour version of Pfizer's heartburn medication.
The agency says is it time to update the onerous decades-old review process.
A panel is meeting February 10 to discuss revoking the OTC status of some medications.
An FDA committee is poised to review a new Primatene Mist in February.
The company beat consensus estimates, with particular sales strengths from its pharmaceuticals division.
Sanofi pulls GLP-1 diabetes med from FDA review; Gilead files oncology drug; BI/Lilly reveals results of head-to-head trial of its SGLT2 inhibitor vs. Januvia; BI campaign animates heartburn market; Girl Scouts take on mental health
The company is supporting its professional pitch for the acne drug with a micro-targeted marketing strategy.
Sanofi may make OTC history; Celgene joins a new collaboration; and the US Task Force of Preventative Medicine wants to make lung cancer screening the norm
FDA grants Teva three years exclusivity to sell Plan B OTC for all ages; FDA gives Humira a thumbs-down for spondyloarthritis; a UK vaccine committee rejects Novartis' meningitis B shot; and Wockhardt gets a warning letter from FDA for its manufacturing practices at an Indian plant.
Researchers quantify the rate at which doctors, nurses and pharmacists buy off-label OTC drugs.
Bridgette Heller, Merck EVP and president of its consumer care division, adjured life-sci managers to enable women to unleash the full power of their knowledge and ideas to drive growth in the business.
A pair of studies suggests that consumers are hungry for information, and that price determines how patients perceive their risk for life-threatening conditions.
CEO Alex Gorsky said OTC brands are coming back. Meanwhile, pharmaceutical sales provided ballast to the year's numbers.
Rolaids gets a French twist, and Elsevier packs the second week of the year with two news items.
Novo Nordisk has launched a hemophilia app; and a report says the Chinese OTC market is going gangbusters
Novartis is hyping its relaunch of Excedrin with a celebrity spokesperson, a migraine app and a survey of women migraine sufferers - along with print and out-of-home ads, radio promotions, direct mail and social media.
A study of advertising for OTC switches found that presentation of risk information plummeted once the products advertised escaped the purview of the FDA.
GlaxoSmithKline continues to shed businesses, but can't shake its weight-loss drug Alli (orlistat).
Novartis named Brian McNamara as division head of OTC, replacing J&J veteran Naomi Kelman, who spent a year in the role.
GlaxoSmithKline divested North American OTC drugs worth about $200 million in sales, a portfolio that seemed like a good strategic fit for buyer Prestige Brands Holdings.
Jon Bon Jovi is the latest celebrity pitchman for Pfizer Consumer Healthcare's Advil.
Don't tell the New York Post, but Pfizer is boosting bike lanes as part of an Advil promotion.
Pfizer is reportedly weighing an attempt at an over-the-counter (OTC) switch for Lipitor - a move that could help the company recoup some of its losses when the $11 billion drug loses US exclusivity in November -- but the reception from analysts has been muted so far.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.